Timolumab
Based on 1 Customer Validation
Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases.
For research use only. We do not sell to patients.
- Purity: 98.56%
- CAS No.: 1073538-99-4
- Molecular Weight:144.44 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG4 kappa
Human
AOC3/VAP1
Timolumab (BTT1023 ) binds to human VAP-1, thereby blocking its function as an adhesion molecule. It also recognizes VAP-1 of other primates and rabbits but does not cross-react with rat or mouse. Timolumab (BTT1023 ) is potentially useful for the treatment and in vivo imaging of inflammatory conditions such as rheumatoid arthritis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1073538-99-4
-
Appearance Liquid
-
Molecular Weight 144.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Timolumab]
-
Synonyms
BTT 1023; Anti-Human AOC3 Recombinant Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ahmad H Ali, et al. Novel treatments in primary sclerosing cholangitis. Clin Liver Dis (Hoboken). 2016 Nov 30;8(5):132-135. [Content Brief]
[2]. Takayuki Inoue, et al. Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema. Bioorg Med Chem. 2013 Mar 1;21(5):1219-33. [Content Brief]
[3]. Anu Autio, et al. Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz